Perrigo’s Pivot To Building Brand Market Share Boosted With Opill OTC Oral Contraceptive Approval

Year after acquiring HRA, Perrigo makes preparations to launch arguably the most anticipated OTC switch in US pharma history, Opill with 0.075-mg norgestel. Analysts estimate $100m annual market for OTC birth control.

• Source: Shutterstock/FDA

Perrigo Company PLC has made notable progress before in its pivot from focusing its US OTC drug business on providing generic copies of OTC national brands to making and marketing national brands.

The transition’s biggest step to date came on 13 July with the Food and Drug Administration’s approval of the application...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

People On The Move: Appointments At Enzymatica, Haleon, Futura

 
• By 

A round up of the latest moves in Europe's consumer health market: Enzymatica appoints CEO; Haleon hires DACH marketing chief; Futura confirms interim CEO.

Over The Counter: Turning Global Ambition Into Local Reality, With Haleon’s Jo Cooper

 
• By 

HBW Insight speaks to Haleon's UK & Ireland general manager Jo Cooper about how she plans to translate the firm's ambitious global growth strategy to a local context.

Futura Launches Eroxon Strategic Review

 
• By 

Weaker than expected sales of OTC ED treatment Eroxon has led Futura to launch a review of the brand's future direction.

Growing With Purpose – Inside Kenvue’s ‘Healthy Lives Mission’

 
• By 

HBW Insight speaks to Kenvue's global head of sustainability, Jennifer Duran, about the company's “Healthy Lives Mission,” including insights into how the firm is decarbonizing its supply chain, reducing the use of plastics and embedding sustainability into the design of new products.

More from Business

Prestige Consumer Starting Clear Eyes Production With No Contract Partner ‘Out There To Tap Into’

 

PCH lowers full-year guidance even after reaching $100m deal to acquire Canadian sterile ophthalmic manufacturer for its Clears Eyes line troubled by supply slumps for several years. Its $47.5m reported net sales for April-June period were down 6% from a year ago.

Futura Launches Eroxon Strategic Review

 
• By 

Weaker than expected sales of OTC ED treatment Eroxon has led Futura to launch a review of the brand's future direction.

Reducing ‘Complexity Across The Organization’ Tops Kenvue Interim CEO’s Priorities

 

Three weeks into his appointment as interim CEO, Kirk Perry sets priorities including “reduce organizational complexity,” “reinforce a consumer-centric mindset” and “refocus on household penetration.”